Company intelligence / Profile preview

ProCore Biomed

Israel

Ownership: Private
Development stage: Other

Overview

ProCore Biomed is commercializing RegenoGel, an injectable viscoelastic hydrogel for joint pain and cartilage regeneration that provides long-term pain relief, is biocompatible, and has established distribution in Israel and ongoing registration efforts in India. No serious adverse effects have been reported. The platform is based on the novel HAProLink hydrogel technology.

Therapeutic areas: Rheumatology
Modalities: Hydrogel-based drug delivery therapyDevice
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on ProCore Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProCore Biomed.

Explore the full profile